

Otonomy, Inc.  
Form 8-K  
November 30, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):**

**November 30, 2016**

**Otonomy, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36591**  
**(Commission**  
  
**File Number)**

**26-2590070**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: Otonomy, Inc. - Form 8-K

**6275 Nancy Ridge Drive, Suite 100**

**San Diego, CA 92121**

**(Address of principal executive offices, including zip code)**

**(858) 242-5200**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On November 30, 2016, Otonomy, Inc. (the Company) is presenting at the ~~28~~<sup>29</sup> Annual Piper Jaffray Healthcare Conference in New York City. At the presentation, the Company is informing the attendees that the Company has fully enrolled its Phase 3 clinical trial of OTIPRIO® in patients with acute otitis externa (AOE), with 262 patients enrolled, and that it expects to announce topline results from this trial as soon as available, which the Company expects to be within four to six weeks.

All of the information furnished in this Item 7.01 shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OTONOMY, INC.**

Date: November 30, 2016

By: /s/ Eric J. Loumeau  
Eric J. Loumeau  
General Counsel and Chief Compliance Officer